Your English writing platform
Discover LudwigSuggestions(2)
Exact(58)
We founded evidence that the use of NMBA in the early phase of ARDS improves outcome, demonstrated by a higher overall ICU survival and survival at day 28, a higher number of ventilator-free days at day 28, an increase in PaO2 to FiO2 ratio, and reduced incidence of barotrauma when compared with the conventional care.
Survival at day 90 was 53.8%.
The primary endpoint will be GVHD free survival at Day 56 post randomization.
Secondary endpoints included global response at the end of intravenous therapy (EOIVT) and at 2 and 6 weeks post-EOT, survival at day 90, and incidence of adverse events (AEs).
The primary endpoint was survival at day +100 post-HSCT; observed rates equaled 38.2% in the defibrotide group and 25% in the controls (23% estimated difference; 95.1% confidence interval [CI], 5.2-40.8 P=.0109, using a propensity-adjusted analysis).
Compound 18 demonstrated EC50 values of 37 and 55 nM versus in vitro cultured parasite strains and promising in vivo efficacy in a Plasmodium berghei antimalarial mouse model, with >50% survival at day 31 post-treatment when administered subcutaneously at 256 mg/kg.
The primary outcome was overall survival at day 60.
Patients were divided into two groups according to survival at day 28.
However, only therapeutic hypothermia improved survival at day 7 (p < 0.05 versus Ctrl).
Similar(2)
While patients undergoing ED exhibited a 19%288 day survival, the survival rate at day 28 in patients without need for dialysis was 40% (p = 0.001).
Typically in humans sepsis usually runs its acute course in 4 12 days, although FDA criteria for drug efficacy require survival data at day 28.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com